文献速递银屑病与炎症性皮肤病

银屑病患者生物制剂暴露后的妊娠结局:大型真实世界安全性队列研究

Pregnancy outcomes in patients with biologic-exposed psoriasis: A large cohort study of real-world safety.
PubMed 文献 · J Am Acad Dermatol · 2026-06-05

该队列研究纳入1226例妊娠期暴露于生物制剂的银屑病患者和1238例未暴露的银屑病对照,比较不良妊娠结局(APO)。生物制剂暴露组任何APO发生率为24.1%,低于未暴露组的30.0%(OR 0.76;95% CI,0.64-0.89;P = .0013)。生物制剂与自然流产、妊娠期糖尿病风险降低相关,未显示APO风险增加。

要点

  • 生物制剂暴露组任何APO发生率24.1%,低于未暴露组的30.0%。
  • 生物制剂与自然流产和妊娠期糖尿病风险降低相关。
  • 生物制剂暴露未增加不良妊娠结局风险。

核心结论

  • 生物制剂暴露的银屑病患者与未暴露对照相比,未显示任何不良妊娠结局风险增加。

研究设计与样本

  • 队列研究,纳入15至49岁妊娠期暴露于生物制剂的女性银屑病患者1226例和未暴露的银屑病对照1238例。

主要发现

  • 任何APO在生物制剂暴露组发生率为24.1%,未暴露对照组为30.0%(OR 0.76;95% CI,0.64-0.89;P = .0013)。
  • 自然流产发生率生物制剂暴露组为8.40%,未暴露组为10.90%(OR 0.75;95% CI,0.57-0.98;P = .0406)。
  • 妊娠期糖尿病发生率生物制剂暴露组为4.16%,未暴露组为7.43%(OR 0.54;95% CI,0.38-0.77;P = .00,054)。

临床怎么用

  • 对于妊娠期银屑病患者,生物制剂暴露未显示增加不良妊娠结局风险,可作为治疗决策参考。

局限性

  • 回顾性设计。
  • 对非TNF-α生物制剂亚类的统计效能有限。
  • 妊娠期暴露持续时间的分 trimester 特征不完整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pregnancy safety data for biologic therapies in psoriasis remain limited. OBJECTIVE: To compare overall and individual adverse pregnancy outcomes (APOs) between reproductive-age women with psoriasis exposed to biologic agents and unexposed psoriasis controls. METHODS: We performed a cohort study including females aged 15 to 49 years exposed to biologics during pregnancy. APOs were compared between biologic-exposed pregnancies and unexposed psoriasis controls. RESULTS: A total of 1226 biologic-exposed psoriasis patients and 1238 unexposed psoriasis controls were included. Any APO occurred in 24.1% of biologic-exposed patients versus 30.0% of unexposed controls (OR 0.76; 95% CI, 0.64-0.89; P = .0013). Biologics were associated with lower odds of spontaneous abortion (8.40% vs 10.90%; OR 0.75; 95% CI, 0.57-0.98; P = .0406), gestational diabetes mellitus (4.16% vs 7.43%; OR 0.54; 95% CI, 0.38-0.77; P = .00,054), and any APO overall. LIMITATIONS: Retrospective design, limited power for non-TNF-α biologic subclasses, and incomplete characterization of trimester-specific exposure duration. CONCLUSIONS: Biologic-exposed psoriasis patients did not exhibit increased risk of any adverse pregnancy outcome compared with unexposed controls.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Bar D, Pavlotsky F, Barzilai A, et al. Pregnancy outcomes in patients with biologic-exposed psoriasis: A large cohort study of real-world safety. J Am Acad Dermatol. 2026. PMID: 42250726. doi:10.1016/j.jaad.2026.06.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。